Currently, Federal Drug Administration approved the use of four chemotherapeutics (methotrexate, bleomycin, docetaxel, and hydroxyurea), one targeted therapy (Cetuximab, monoclonal antibody against EGFR), and one drug combination (docetaxel, cisplatin, and 5-fluorouracil) for treatment of HNSCC. Here, EGFR is linked to head and neck squamous cell carcinoma.